BIO Company is a private company. It employs 30 engineers and scientists who are involved with research and development of various biomedical devices. All of the engineers and scientists are highly regarded and highly paid in the field of biomedical research. BIO is 50% owned by Rod Smart, who started the company in Year 3, and 50% owned by a group of venture capitalists who contributed $10 million of equity capital in Year 4 to fund the R&D activity of the group.

On January 1, Year 6, REX Ltd., a public company listed on the TSX Venture Exchange, acquired 100% of the shares of BIO by issuing 5 million of its own shares. Its shares were trading at $4 per share on the date of this transaction.

The balance sheet for BIO on January 1, Year 6, was as follows:

Cash and marketable securities $2,500,000

Property, plant, and equipmentnet 800,000

Development costs 3,000,000

$6,300,000

Liabilities $ 900,000

Common shares 10,100,000

Deficit (4,700,000)

$6,300,000

The cash, marketable securities, property, plant, and equipment, and liabilities have fair values equal to carrying amounts. Prior to Year 5, all of the research and development costs were expensed. Starting in Year 5, the developments costs were capitalized because the management of BIO felt that they were getting close to patenting some of their products.

The management of REX is aware that BIO will need to be included in REX's consolidated financial statements. They hired you as a consultant to prepare a memo, answering questions, concerning these consolidated financial statements.

(a)

Will any part of the acquisition cost be allocated to BIO's skilled workers? If so, how will this asset be measured, and how will it be amortized or checked for impairment on an annual basis?

Please answer based on Canadian standards.